You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameGM6001
Accession NumberDB02255  (EXPT01618)
TypeSmall Molecule
GroupsExperimental
DescriptionNot Available
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIII0403ML141
CAS numberNot Available
WeightAverage: 388.4607
Monoisotopic: 388.211055404
Chemical FormulaC20H28N4O4
InChI KeyInChIKey=NITYDPDXAAFEIT-DYVFJYSZSA-N
InChI
InChI=1S/C20H28N4O4/c1-12(2)8-13(10-18(25)24-28)19(26)23-17(20(27)21-3)9-14-11-22-16-7-5-4-6-15(14)16/h4-7,11-13,17,22,28H,8-10H2,1-3H3,(H,21,27)(H,23,26)(H,24,25)/t13-,17+/m1/s1
IUPAC Name
(2R)-N'-hydroxy-N-[(1S)-2-(1H-indol-3-yl)-1-(methylcarbamoyl)ethyl]-2-(2-methylpropyl)butanediamide
SMILES
[H][C@@](CC(C)C)(CC(=O)NO)C(=O)N[C@@]([H])(CC1=CNC2=CC=CC=C12)C(=O)NC
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-acyl-alpha amino acids and derivatives. These are compounds containing an alpha amino acid (or a derivative thereof) which bears an acyl group at its terminal nitrogen atom.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentN-acyl-alpha amino acids and derivatives
Alternative Parents
Substituents
  • N-acyl-alpha amino acid or derivatives
  • Triptan
  • Alpha-amino acid amide
  • Indole or derivatives
  • Indole
  • Fatty acyl
  • Benzenoid
  • Substituted pyrrole
  • N-acyl-amine
  • Fatty amide
  • Heteroaromatic compound
  • Pyrrole
  • Secondary carboxylic acid amide
  • Hydroxamic acid
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationNot Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9257
Blood Brain Barrier+0.7174
Caco-2 permeable-0.6893
P-glycoprotein substrateSubstrate0.6278
P-glycoprotein inhibitor INon-inhibitor0.8441
P-glycoprotein inhibitor IINon-inhibitor0.9049
Renal organic cation transporterNon-inhibitor0.9516
CYP450 2C9 substrateNon-substrate0.8618
CYP450 2D6 substrateNon-substrate0.7876
CYP450 3A4 substrateSubstrate0.6018
CYP450 1A2 substrateNon-inhibitor0.7874
CYP450 2C9 inhibitorNon-inhibitor0.8053
CYP450 2D6 inhibitorNon-inhibitor0.8911
CYP450 2C19 inhibitorNon-inhibitor0.7102
CYP450 3A4 inhibitorNon-inhibitor0.8667
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9376
Ames testNon AMES toxic0.6111
CarcinogenicityNon-carcinogens0.8187
BiodegradationNot ready biodegradable0.9965
Rat acute toxicity2.4741 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9946
hERG inhibition (predictor II)Non-inhibitor0.9059
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0408 mg/mLALOGPS
logP1.23ALOGPS
logP1.15ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)8.9ChemAxon
pKa (Strongest Basic)-0.71ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area123.32 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity105.17 m3·mol-1ChemAxon
Polarizability41.04 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with GM6001.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with GM6001.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with GM6001.
AmineptineThe serum concentration of Amineptine can be increased when it is combined with GM6001.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with GM6001.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with GM6001.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with GM6001.
BoceprevirThe serum concentration of GM6001 can be decreased when it is combined with Boceprevir.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with GM6001.
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with GM6001.
CarbamazepineThe metabolism of GM6001 can be increased when combined with Carbamazepine.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with GM6001.
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with GM6001.
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with GM6001.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with GM6001.
CyclophosphamideThe risk or severity of adverse effects can be increased when GM6001 is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with GM6001.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with GM6001.
DesipramineThe serum concentration of Desipramine can be increased when it is combined with GM6001.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with GM6001.
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with GM6001.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with GM6001.
DoxepinThe serum concentration of Doxepin can be increased when it is combined with GM6001.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with GM6001.
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with GM6001.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with GM6001.
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with GM6001.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with GM6001.
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with GM6001.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with GM6001.
GarlicThe serum concentration of GM6001 can be decreased when it is combined with Garlic.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with GM6001.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with GM6001.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with GM6001.
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with GM6001.
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with GM6001.
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with GM6001.
PethidineThe risk or severity of adverse effects can be increased when GM6001 is combined with Pethidine.
PimozideThe serum concentration of Pimozide can be increased when it is combined with GM6001.
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with GM6001.
RiociguatThe serum concentration of Riociguat can be increased when it is combined with GM6001.
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with GM6001.
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with GM6001.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with GM6001.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with GM6001.
St. John's WortThe metabolism of GM6001 can be increased when combined with St. John's Wort.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with GM6001.
TemsirolimusThe risk or severity of adverse effects can be increased when GM6001 is combined with Temsirolimus.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with GM6001.
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with GM6001.
TipranavirThe serum concentration of GM6001 can be decreased when it is combined with Tipranavir.
TriazolamThe serum concentration of Triazolam can be increased when it is combined with GM6001.
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with GM6001.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with GM6001.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Bacillus anthracis
Pharmacological action
unknown
General Function:
Metallopeptidase activity
Specific Function:
One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. LF is the lethal factor that, when associated with PA, causes death. LF is not toxic by itself. It is a protease that cleaves the N-terminal of most dual specificity mitogen-activated protein kinase kinases (MAPKKs or MAP2Ks) (except for MAP2K5). Cleavage invariably oc...
Gene Name:
lef
Uniprot ID:
P15917
Molecular Weight:
93769.58 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Zinc ion binding
Specific Function:
May play a role in the adhesive and proteolytic events that occur during lymphocyte emigration or may function in ectodomain shedding of lymphocyte surface target proteins, such as FASL and CD40L. May be involved in sperm maturation.
Gene Name:
ADAM28
Uniprot ID:
Q9UKQ2
Molecular Weight:
87147.04 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Metal ion binding
Specific Function:
This proteoglycan is a major component of extracellular matrix of cartilagenous tissues. A major function of this protein is to resist compression in cartilage. It binds avidly to hyaluronic acid via an N-terminal globular region.
Gene Name:
ACAN
Uniprot ID:
P16112
Molecular Weight:
250190.95 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23